Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2174/1874471008666150312124009 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Editorial: Recent advances in radiotheranostics.
Front Nucl Med
November 2024
Departmen of Nuclear Engineering, University of Tennessee-Knoxville, Knoxville, TN, United States.
Correlating Prostate-specific Antigen Dynamics with Outcomes of Lutetium-177-PSMA-617 Treatment: Refining Predictive and Prognostic Biomarkers.
Eur Urol
December 2024
Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA. Electronic address:
Evaluation of a blood miRNA/mRNA signature to follow-up Lu-PRRT therapy for G1/G2 intestinal neuroendocrine tumors.
Front Endocrinol (Lausanne)
July 2024
Biochemistry Laboratory, Federative Institute of Biology, Academic Hospital, Toulouse, France.
Background: Lu-oxodotreotide peptide receptor therapy (LuPRRT) is an efficient treatment for midgut neuroendocrine tumors (NETs) of variable radiological response. Several clinical, biological, and imaging parameters may be used to establish a relative disease prognosis but none is able to predict early efficacy or toxicities. We investigated expression levels for mRNA and miRNA involved in radiosensitivity and tumor progression searching for correlations related to patient outcome during LuPRRT therapy.
View Article and Find Full Text PDFLutetium [Lu]-DOTA-TATE in gastroenteropancreatic-neuroendocrine tumours: rationale, design and baseline characteristics of the Italian prospective observational (REAL-LU) study.
Eur J Nucl Med Mol Imaging
September 2024
Nuclear Medicine Unit, IRCCS-Fondazione Istituto Nazionale dei Tumori, Milan, Italy.
Purpose: Gastroenteropancreatic -neuroendocrine tumours (GEP-NETs) are commonly treated with surgical resection or long-term therapies for tumour growth control. Lutetium [Lu]-DOTA-TATE was approved for the treatment of GEP-NETs after the phase III NETTER 1trial demonstrated improved progression free survival, objective response rates and health-related quality of life (HRQoL) compared to high-dose somatostatin analogues. No real-world data exist on prescribing habits and clinically significant endpoints for [Lu]Lu-DOTA-TATE treatment in Italy.
View Article and Find Full Text PDFA Review of Theranostics: Perspectives on Emerging Approaches and Clinical Advancements.
Radiol Imaging Cancer
July 2023
From the Department of Radiology (B.J.B., D.J.B., D.R.J., M.K.P., A.T.P., C.B.H., G.B.J., A.T.K.) and Division of Medical Oncology (P.W.M., A.R.L., T.R.H.), Mayo Clinic, 200 First St SW, Rochester, MN 55905; and Department of Nuclear Medicine, Anadolu Medical Center, Gebze/Kocaeli, Turkey (K.B.).
Theranostics is the combination of two approaches-diagnostics and therapeutics-applied for decades in cancer imaging using radiopharmaceuticals or paired radiopharmaceuticals to image and selectively treat various cancers. The clinical use of theranostics has increased in recent years, with U.S.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!